先聲藥業(2096.HK)逆勢拉昇漲超5%
格隆匯10月29日丨先聲藥業(2096.HK)今日盤中逆勢拉昇,一度漲5.64%報11.62港元,創上市新高價,市值一度達302.8億港元。先聲藥業於10月27日在港掛牌上市,此次IPO募集資金30多億,用於重點治療領域在研產品的研發,包括腫瘤疾病在研產品。招股書顯示,先聲藥業的總收入由2017年的人民幣38.68億元增加至2019年的50.37億元,年複合增長率為14.1%;淨利潤由2017年的3.50億元增加至2019年的10.04億元,年複合增長率為69.2%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.